Britain's Court of Appeal on Wednesday upheld a ruling protecting a key European patent for Pfizer's blockbuster cholesterol drug, Lipitor. A panel of three judges rejected an appeal by Indian drug maker Ranbaxy Laboratories Ltd. against an October High Court decision upholding the patent, which expires in 2011. Ranbaxy had wanted to release a generic version of the drug in Britain. Lipitor is the world's best-selling drug and brings in more than $12 billion a year for Pfizer.
June 29, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Britain’s Court of Appeal on Wednesday upheld a ruling protecting a key European patent for Pfizer Inc.’s best-selling cholesterol drug, Lipitor.
A panel of three judges rejected an appeal by Indian drug maker Ranbaxy Laboratories Ltd. against an October High Court decision upholding the patent, which expires in 2011.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
